ZA200711105B - Novel physiological substance nesfatin substance relevant thereto, and use of the substances - Google Patents

Novel physiological substance nesfatin substance relevant thereto, and use of the substances

Info

Publication number
ZA200711105B
ZA200711105B ZA200711105A ZA200711105A ZA200711105B ZA 200711105 B ZA200711105 B ZA 200711105B ZA 200711105 A ZA200711105 A ZA 200711105A ZA 200711105 A ZA200711105 A ZA 200711105A ZA 200711105 B ZA200711105 B ZA 200711105B
Authority
ZA
South Africa
Prior art keywords
substance
nesfatin
substances
relevant
novel physiological
Prior art date
Application number
ZA200711105A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Masanori Yamamoto
Masatomo Mori
Hiroyuki Shimizu
Original Assignee
Teijin Pharma Ltd
Univ Corp Gunma University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Univ Corp Gunma University filed Critical Teijin Pharma Ltd
Publication of ZA200711105B publication Critical patent/ZA200711105B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
ZA200711105A 2005-06-24 2007-12-20 Novel physiological substance nesfatin substance relevant thereto, and use of the substances ZA200711105B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005184441 2005-06-24
JP2006064678 2006-03-09

Publications (1)

Publication Number Publication Date
ZA200711105B true ZA200711105B (en) 2009-08-26

Family

ID=37570595

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200711105A ZA200711105B (en) 2005-06-24 2007-12-20 Novel physiological substance nesfatin substance relevant thereto, and use of the substances

Country Status (15)

Country Link
EP (1) EP1900813A4 (ja)
JP (1) JP5640230B2 (ja)
KR (1) KR20080028888A (ja)
CN (1) CN101300346B (ja)
AU (1) AU2006260088B2 (ja)
BR (1) BRPI0612279A2 (ja)
CA (1) CA2613257A1 (ja)
IL (1) IL188288A (ja)
NO (1) NO20080412L (ja)
NZ (1) NZ565253A (ja)
RU (1) RU2418002C2 (ja)
SG (2) SG165386A1 (ja)
TW (1) TWI395948B (ja)
WO (1) WO2006137597A1 (ja)
ZA (1) ZA200711105B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986008A1 (en) * 2007-04-06 2008-10-29 Teijin Pharma Limited A method for screening a regulator of nesfatin-1 function or a nesfatin-1 like substance using receptor protein selected from the group consisting of GPR3, GPR6 and GPR12
WO2009025401A1 (en) * 2007-08-23 2009-02-26 Teijin Pharma Limited Nesfatin-1 specific antibody and the use thereof, and nesfatin specific antibody and the use thereof
JP4691571B2 (ja) * 2008-03-04 2011-06-01 株式会社マルハニチロ食品 摂食調節剤
US8703707B2 (en) * 2008-07-17 2014-04-22 The Rockefeller University Nucleobindin I variant protein compositions and methods of use
WO2010028676A1 (en) * 2008-09-09 2010-03-18 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US9018159B2 (en) 2009-03-12 2015-04-28 Landing Biotech, Inc. Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof
EP2229952B1 (en) * 2009-03-12 2014-08-13 Jian-Ning Liu Plasma anti-diabetic NUCB2 peptide (pladin and nesfatin-1n) and uses thereof
CN104918639B (zh) 2012-10-22 2018-01-26 萨拜格Rfa公司 用于将治疗剂递送到活细胞和细胞核中的系统
CN106589101A (zh) * 2016-11-30 2017-04-26 青岛大学 一种nesfatin多肽及其相关物质和用途
CN108949880B (zh) * 2018-08-03 2021-07-20 吉林大学 一种牛脊髓肽的制备方法及其应用
CN114761418A (zh) * 2019-12-02 2022-07-15 株式会社Lg化学 Cho细胞衍生的蛋白分泌因子和包含它的表达载体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
CA1332049C (en) 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
JP2002017186A (ja) 2000-06-30 2002-01-22 Hayashibara Biochem Lab Inc トランスジェニック植物
JP2003116385A (ja) 2001-10-15 2003-04-22 Univ Of The Ryukyus 日本脳炎ワクチンをコードする遺伝子を含むトランスジェニック植物
JP2003342201A (ja) 2002-03-20 2003-12-03 Cardio Corp 遺伝子細胞治療剤
JP3887658B2 (ja) 2002-03-27 2007-02-28 新潟県 遺伝子導入用の植物細胞処理装置

Also Published As

Publication number Publication date
KR20080028888A (ko) 2008-04-02
JP5640230B2 (ja) 2014-12-17
CA2613257A1 (en) 2006-12-28
SG165386A1 (en) 2010-10-28
AU2006260088A1 (en) 2006-12-28
TW200741205A (en) 2007-11-01
RU2418002C2 (ru) 2011-05-10
WO2006137597A1 (ja) 2006-12-28
RU2008102731A (ru) 2009-07-27
AU2006260088B2 (en) 2012-07-12
CN101300346A (zh) 2008-11-05
NZ565253A (en) 2011-06-30
JPWO2006137597A1 (ja) 2009-01-22
EP1900813A4 (en) 2009-08-05
CN101300346B (zh) 2013-04-24
TWI395948B (zh) 2013-05-11
NO20080412L (no) 2008-03-18
BRPI0612279A2 (pt) 2009-01-27
WO2006137597A9 (ja) 2008-05-29
IL188288A0 (en) 2008-04-13
IL188288A (en) 2013-08-29
SG165385A1 (en) 2010-10-28
EP1900813A1 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
ZA200711105B (en) Novel physiological substance nesfatin substance relevant thereto, and use of the substances
IL191655A0 (en) Novel compounds, their preparation and use
EP1833482A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
GB0512940D0 (en) Compounds and their use
EP1968649A4 (en) NANOPARTICLES OF PROTEINS AND THEIR USE
EP1951682A4 (en) NEW 2-AMINOPYRIMIDONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE
GB0516069D0 (en) Pharmaceutical and use thereof
GB0520743D0 (en) Compounds and their use
IL190519A0 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
TWI367222B (en) Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
IL191067A0 (en) Micronised azodicarbonamide, the preparation and use thereof
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
IL185575A0 (en) Benzoxazocines and their therapeutic use
EP1767210A4 (en) MEDICAL USE OF PAEONIFLORIN
IL185691A0 (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
EP1897884A4 (en) PHYSIOLOGICALLY ACTIVE SUBSTANCE NK13650P3, PROCESS FOR PRODUCTION THEREOF AND USE THEREOF
GB0421766D0 (en) Compounds and their medical uses
GB0421767D0 (en) Compounds and their medical uses
GB0427723D0 (en) Compounds and their use
GB2425708B (en) Bracelet and use thereof
GB0521278D0 (en) Compounds and their use
GB0513176D0 (en) Compounds and their use
GB0505383D0 (en) Diagnosis and treatment
ZA200708862B (en) Novel oxadiazole derivatives and their medical use